The demand for factor VIII and for factor IX and the toll fractionation product surplus management

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Calizzani, Gabriele ^a   Profili, Samantha ^a   Candura, Fabio ^a   Lanzoni, Monica ^a,b   Vaglio, Stefania ^a,c   Cannata, Livia ^a   Liumbruno, Giancarlo M ^d   Franchini, Massimo ^e   Mannucci, Pier Mannuccio ^b   Grazzini, Giuliano ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b FONDAZIONE IRCCS CA GRANDA OSPEDALE MAGGIORE POLICLINICO   (Italy)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

^d SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^e CARLO POMA HOSPITAL   (Italy)

Author keywords

Demand; Factor IX; Factor VIII; Plasma derived medicinal products; Surplus management

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 9 CONCENTRATE; EMOCLOT; FANHDI; FIXNOVE; HAEMOBIONNE; HAEMOCTIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; UNCLASSIFIED DRUG;

COMPARATIVE STUDY; DRUG INDICATION; DRUG USE; GEOGRAPHIC DISTRIBUTION; HEMOPHILIA A; HEMOPHILIA B; HUMAN; REVIEW;

COAGULANTS; FACTOR IX; FACTOR VIII; HUMANS; MEDICATION THERAPY MANAGEMENT;

EID: 84885580434     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.011s     Document Type: Review

References (46)

1. Guideline on core Summary of Product Characteristics for human plasma derived and recombinant coagulation factor VIII products. EMA/CHMP/BPWP/1619/ 1999 Rev.1. European Medicine Agency. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128995.pdf. Accessed on 22/08/2013.
2. Guideline on core Summary of Product Characteristics for human plasma derived and recombinant coagulation factor VIII products. EMA/CHMP/BPWP/1625/ 1999 Rev 1. European Medicine Agency. Available at: http://www.ema.europa.eu/ docs/en-GB/document-library/Scientific-guideline/2012/06/WC500128995.pdf. Accessed on 22/08/2013.
3. Stonebraker JS, Bolton-Maggs PHB, Michael Soucie J, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
4. Stonebraker JS, Bolton-Maggs PHB, Michael Soucie J, et al. A study of variations in the reported haemophilia B prevalence around the world. Haemophilia 2012; 18: e91-4.
5. Gringeri A. Treatment protocol of haemophilia and other congenital bleeding disorders in Italy. Italian Association of Hemophilia Centers (AICE). Haemophilia 1998 Jul;4: 423-4. (Pubitemid 28351860)
6. Data Summaries, Italian Registry Of Haemophilia And Allied Disorders. Italian Association of Hemophilia Centres (AICE). Available at: http://www.aiceonline.it/emocard/summaries. htm. Accessed on 22/08/2013.
7. Mannucci PM, Ruggeri ZM, Pareti FI, et al. A1-Deamino-8-darginine vasopressin: a new pharmacological approach to the management of haemophilia and von Willebrands' diseases. Lancet 1977; 23; 1: 869-72. (Pubitemid 8079684)
8. Franchini M, Mannucci PM. Hemophilia A in the third millennium. Blood Rev 2013; 274: 179-84.
9. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
10. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost 2009; 101: 674-81.
11. Gringeri A, Lundin B, von Mackensen S, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
12. Makris M. Prophylaxis in haemophilia should be life-long. Blood Transfus 2012; 10: 165-8.
13. Tagliaferri A, Rivolta GF, Iorio A, et al. Italian Association of Hemophiliac Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
14. Burnouf T. Modern plasma fractionation. Transfus Med Rev 2007; 21: 101-17. (Pubitemid 46482990)
15. Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-62. (Pubitemid 351705301)
16. th International Standard Factor VIII concentrate. World Health Organization Available at: http://www.nibsc.org/ documents/ifu/07-350.pdf. Accessed on: 22/08/2013.
17. Mannucci PM, Franchini M, Castaman G, et al. Evidencebased recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
18. Wood WI, Capon DJ, Simonsen CC, et al. Expression of active human factor VIII from recombinant DNA clones. Nature 1984; 312: 330-7. (Pubitemid 15209309)
19. White GC 2nd, Mc Millan CW, Kingdon HS, et al. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70. (Pubitemid 19033095)
20. Franchini M, Lippi G. Recombinant FVIII concentrates. Semin Thromb Hemost 2010; 36: 493-7.
21. th International Standard for Factor IX, Plasma, Human distributed. World Health Organization. Available at: http://www.nibsc.org/ documents/ifu/09-172.pdf. Accessed on 22/08/2013.
22. Franchini M, Frattini F, Crestani S, et al. Treatment of hemophilia B: focus on recombinant factor IX. Biologics. 2013; 7: 33-8.
23. Lanzoni M, Biffoli C, Candura F, et al. Plasma-derived medicinal products in Italy: information sources and flows. Blood Transfus 2013; 11 (Suppl 4): s13-7.
24. Robert P; The Marketing Research Bureau (MRB). The Worldwide Plasma Fractions Market 2008. April 2010 Ed. Orange, CT: The Marketing Research Bureau, Inc.; 2010.
25. World Federation of Hemophilia. Report on the Annual Global Survey 2010. World Federation of Hemophilia. Montreal, 2011. Available at http://www1.wfh.org/publications/files/pdf-1427.pdf. Accessed on 22/08/13.
26. O'Mahony B, Noone D, Giangrande P. L. F., Prihodova L. Haemophilia care in Europe - a survey of 35 countries. Haemophilia 2013; 19: e239-47.
27. Calizzani G, Vaglio S, Profili S, et al. The regulatory framework of the plasma and plasma-derived medicinal products system in Italy. Blood Transfus 2013; 11 (Suppl 4): s6-12.
28. Calizzani G, Lanzoni M, Candura F, et al. Analisi della domanda dei principali medicinali plasmaderivati in Italia. Anni 2007-2011. Roma: Istituto Superiore di Sanità 2012. Rapporti ISTISAN 12/53. Available at: http://www.iss.it/binary/publ/cont/dodici53web.pdf. Accessed on 22/08/2013.
29. Grazzini G, Rossi G, Rafanelli D, et al. Quality control of recovered plasma for fractionation: an extensive Italian study. Transfusion 2008; 48: 1459-68.
30. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
31. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl 3): 10-8. (Pubitemid 351722377)
32. Mannucci PM. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: plasmaderived is better. Blood Transfus 2010; 8: 288-91.
33. Franchini M. Plasma-derived versus recombinant factor VIII concentrates for the treatment of haemophilia A: recombinant is better. Blood Transfus 2010; 8: 292-6.
34. Calizzani G, Arcieri R. Clinical and organisational aspects of haemophilia care: the patients' view. Blood Transfus 2012; 10: 110-1.
35. Gringeri A. Factor VIII safety: plasma-derived versus recombinant products. Blood Transfus 2011; 9: 366-70.
36. Mannucci PM, Mancuso ME, Santagostino E. How we choose factor VIII to treat hemophilia. Blood 2012; 119: 4108-14.
37. Annual Report 2008-2009. National Blood Authority Australia. Available at http://www.blood.gov.au/pubs/0809report/partThree/3-4.html. Accessed on 22/08/2013.
38. WHO Expert Group. Expert Consensus Statement on achieving self-sufficiency in safe blood and blood products, based on voluntary non-remunerated blood donation (VNRBD). Vox Sang 2012; 103: 337-42.
39. O'Mahony B., Turner A. The Dublin Consensus Statement on vital issues relating to the collection of blood and plasma and the manufacture of plasma products. Vox Sanguinis 2010; 98: 447-50.
40. th list (April 2013). World Health Organization. Available at: http://www.who.int/medicines/ publications/essentialmedicines/18th-EML-Final-web-8Jul13.pdf. Accessed on 22/08/2013.
41. th list (April 2013). World Health Organization. Available at: http://www.who.int/ medicines/publications/essentialmedicines/4th-EMLc-FINAL-web-8Jul13.pdf. Accessed on 22/08/2013.
42. Skinner MW. Haemophilia: provision of factors and novel therapies: World Federation of Hemophilia goals and achievements. Br J Haematol 2011; DOI 10.1111/j.1365-2141.2011.08765.x.
43. th, 2005. Legge 21 ottobre 2005, n. 219 "Nuova disciplina delle attività trasfusionali e della produzione nazionale degli emoderivati". Available at: http://www.centronazionalesangue.it/content/legge-21-ottobre-2005-2-219. Accessed on 22/08/2013.
44. Grazzini G, Ceccarelli A, Calteri D, et al. Sustainability of a public system for plasma collection, contract fractionation and plasma-derived medicinal products manufacturing. Blood Transfus 2013; 11 (Suppl 4): s138-47.
45. th, 2012. Decreto del Ministro della Salute 12 aprile 2012 "Disposizioni sull'importazione ed esportazione del sangue umano e dei suoi prodotti". Available at: http://www.centronazionalesangue.it/sites/default/files/dd.mm-.- 12.04.2012-plasma-gu-n.-147-del-26.06.2012-.pdf. Accessed on 22/08/2013.
46. th, 2013. Accordo 7 febbraio 2013, ai sensi dell'articolo 4 del decreto legislativo 28 agosto 1997, n. 281, tra il Governo, le regioni e le province autonome di Trento e Bolzano per la promozione ed attuazione di accordi di collaborazione per l'esportazione di prodotti plasmaderivati ai fini umanitari. Available at: http://fedemo.it/wp-content/uploads/2013/07/Accordo-CSR-07.02.2013-GU-n.-107-09. 05.2013-Esportazioneplasmaderivati-fini-umanitari.pdf. Accessed on 22/08/2012.